Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 52.3 CHF 1.75% Market Closed
Market Cap: 633.9m CHF

Wall Street
Price Targets

BSLN Price Targets Summary
Basilea Pharmaceutica AG

Wall Street analysts forecast BSLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BSLN is 80.92 CHF with a low forecast of 64.64 CHF and a high forecast of 110.25 CHF.

Lowest
Price Target
64.64 CHF
24% Upside
Average
Price Target
80.92 CHF
55% Upside
Highest
Price Target
110.25 CHF
111% Upside
Basilea Pharmaceutica AG Competitors:
Price Targets
145020
Hugel Inc
72% Upside
300676
BGI Genomics Co Ltd
29% Upside
196170
Alteogen Inc
24% Upside
4587
PeptiDream Inc
104% Upside
ONCO
Oncopeptides AB
1% Downside
EXAS
Exact Sciences Corp
1% Downside
TGTX
TG Therapeutics Inc
41% Upside
BMEA
Biomea Fusion Inc
370% Upside

Revenue
Forecast

Revenue Estimate
Basilea Pharmaceutica AG

For the last 13 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 9%. The projected CAGR for the next 3 years is 11%.

9%
Past Growth
11%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 3 years is -14%.

N/A
Past Growth
-14%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Net Income
Forecast

Net Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 3 years is -15%.

N/A
Past Growth
-15%
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BSLN's stock price target?
Price Target
80.92 CHF

According to Wall Street analysts, the average 1-year price target for BSLN is 80.92 CHF with a low forecast of 64.64 CHF and a high forecast of 110.25 CHF.

What is Basilea Pharmaceutica AG's Revenue forecast?
Projected CAGR
11%

For the last 13 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 9%. The projected CAGR for the next 3 years is 11%.

What is Basilea Pharmaceutica AG's Operating Income forecast?
Projected CAGR
-14%

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 3 years is -14%.

What is Basilea Pharmaceutica AG's Net Income forecast?
Projected CAGR
-15%

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 3 years is -15%.

Back to Top